[go: up one dir, main page]

WO2001040460A8 - Screening method for compounds capable of modularing egr-1-regulated expression - Google Patents

Screening method for compounds capable of modularing egr-1-regulated expression

Info

Publication number
WO2001040460A8
WO2001040460A8 PCT/EP2000/011997 EP0011997W WO0140460A8 WO 2001040460 A8 WO2001040460 A8 WO 2001040460A8 EP 0011997 W EP0011997 W EP 0011997W WO 0140460 A8 WO0140460 A8 WO 0140460A8
Authority
WO
WIPO (PCT)
Prior art keywords
egr
modularing
screening method
compounds capable
regulated expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/011997
Other languages
French (fr)
Other versions
WO2001040460A1 (en
Inventor
Martin Braddock
Callum Jeffrey Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU25092/01A priority Critical patent/AU2509201A/en
Priority to EP00988766A priority patent/EP1244786A1/en
Priority to US10/148,055 priority patent/US20030124554A1/en
Priority to JP2001542527A priority patent/JP2003515339A/en
Publication of WO2001040460A1 publication Critical patent/WO2001040460A1/en
Publication of WO2001040460A8 publication Critical patent/WO2001040460A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

An Egr-1 expression system can be provided and used to screen for moieties capable of regulating Egr-1 expression. Such moieties can be used as medicaments or in drug development programs, particularly in the identification of drugs for wound healing.
PCT/EP2000/011997 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression Ceased WO2001040460A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU25092/01A AU2509201A (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression
EP00988766A EP1244786A1 (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression
US10/148,055 US20030124554A1 (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression
JP2001542527A JP2003515339A (en) 1999-12-01 2000-11-30 Screening method for compounds capable of regulating EGR-1 regulatory expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9928430.9 1999-12-01
GBGB9928430.9A GB9928430D0 (en) 1999-12-01 1999-12-01 Screening

Publications (2)

Publication Number Publication Date
WO2001040460A1 WO2001040460A1 (en) 2001-06-07
WO2001040460A8 true WO2001040460A8 (en) 2001-11-08

Family

ID=10865529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011997 Ceased WO2001040460A1 (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression

Country Status (5)

Country Link
EP (1) EP1244786A1 (en)
JP (1) JP2003515339A (en)
AU (1) AU2509201A (en)
GB (1) GB9928430D0 (en)
WO (1) WO2001040460A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106488A2 (en) * 2006-03-13 2007-09-20 Wyeth Modulators of gluconeogenesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
AUPN855496A0 (en) * 1996-03-07 1996-04-04 Unisearch Limited Prevention of proliferation of vascular cells
NZ508505A (en) * 1998-06-02 2003-04-29 Glaxo Group Ltd Treatment of wounds using an Egr-1 transcription factor polypeptide
PL345507A1 (en) * 1998-07-11 2001-12-17 Glaxo Group Ltd Pharmaceutical uses of nab1 and nab2

Also Published As

Publication number Publication date
EP1244786A1 (en) 2002-10-02
AU2509201A (en) 2001-06-12
GB9928430D0 (en) 2000-01-26
JP2003515339A (en) 2003-05-07
WO2001040460A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
ZA987540B (en) Process for the preparation of stanol esters, and use thereof.
AU3718797A (en) Nonocclusive drug delivery device and process for its manufacture
AU2003298715A1 (en) System, method and computer program product for the delivery of media content
AU2002219174A1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
AU3912700A (en) Method and system for healthcare treatment, planning, and assessment
AU3593597A (en) Medical adhesive bandage, delivery system and method
EP1078628A3 (en) Multiple unit tableted dosage form
IL90435A0 (en) 4-(quinolin-2-yl-methoxy)phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
AU6271401A (en) Drug administering system and administering method
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
AU1958701A (en) A system and method for the delivery, retrieval and display of content prior to operating system loading
IL148870A (en) 2'-substituted 1,1'-biphenyl - 2 - carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
HUP0102921A3 (en) Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
AU9002598A (en) Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
AU6062498A (en) Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use
AU3156600A (en) Novel epothilon derivatives, method for the production thereof and their pharmaceutical application
AU2841199A (en) Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine
HUP9903353A3 (en) 7alpha-(methyl-amino-pentyl)-estratrienes, pharmaceutical preparations which contain said 7alpha-(5-methylaminopentyl) -estratrienes and use thereof for production of drugs
AU5475300A (en) System, method and computer program product for generating an inventory-centric demographic hyper-cube
WO2001040460A8 (en) Screening method for compounds capable of modularing egr-1-regulated expression
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
SI1165528T1 (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
HRP980527B1 (en) Sulfonamid-substituted chromans, process for their preparation, their use as medicine, and pharmaceutical preparation containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000988766

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10148055

Country of ref document: US

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 542527

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000988766

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000988766

Country of ref document: EP